 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | New P1 trial: Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia. (clinicaltrials.gov) - Jul 9, 2019
P1, N=50, Recruiting, Sponsor: Wuhan Union Hospital, China